SCHEMBL1632425

SCHEMBL1632425

Fc1ccc(Nc2ncc3cccc(-c4ccc(NCCN5CCCC5)nc4)c3n2)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.47
KDR P35968 3/20 0.47
FGFR2 P21802 3/20 0.47
MAPK10 P53779 3/20 0.45
SIGMAR1 Q99720 5/20 0.43
TMEM97 Q5BJF2 1/20 0.43
CSF1R P07333 1/20 0.40
MAP3K11 Q16584 1/20 0.40
PIK3CA P42336 1/20 0.39
POLB P06746 1/20 0.39
KCNH2 Q12809 1/20 0.38
TTK P33981 1/20 0.38
JUN P05412 2/20 0.37
PIM1 P11309 1/20 0.37
PIM2 Q9P1W9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634397 0.89 MAPK10 (0.59) FGFR1KDRFGFR2MAPK10SIGMAR1
SCHEMBL1634203 0.88 MAPK10 (0.48) FGFR1KDRFGFR2MAPK10SIGMAR1
SCHEMBL1631565 0.88 MAPK10 (0.48) FGFR1KDRFGFR2MAPK10SIGMAR1
SCHEMBL1633357 0.86 MAPK10 (0.47) FGFR1KDRFGFR2MAPK10SIGMAR1
SCHEMBL1634890 0.84 MAPK10 (0.47) KDRFGFR2MAPK10MAP3K11JUN
SCHEMBL1633913 0.82 JAK3 (0.48) FGFR1KDRFGFR2MAPK10CSF1R
SCHEMBL1633364 0.82 KDR (0.45) KDRFGFR2MAPK10MAP3K11POLB
SCHEMBL1633503 0.81 MAPK10 (0.47) FGFR1KDRFGFR2MAPK10MAP3K11
SCHEMBL1632057 0.81 GBA1 (0.45) FGFR1KDRFGFR2MAPK10JUN
SCHEMBL1631314 0.81 CTSC (0.45) KDRFGFR2MAPK10POLBJUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed